Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation
- 1 January 2016
- journal article
- research article
- Published by Walter de Gruyter GmbH in cclm
- Vol. 54 (6)
- https://doi.org/10.1515/cclm-2015-1023
Abstract
Background: The use of therapeutic recombinant monoclonal antibodies (mAbs) has triggered concerns of mis-diagnosis of a plasma cell dyscrasia in treated patients. The purpose of this study is to determine if infliximab (INF), adalimumab (ADA), eculizumab (ECU), vedolizumab (VEDO), and rituximab (RITU) are detected as monoclonal proteins by serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE).Methods: Pooled normal sera were spiked with various concentrations (ranging from trough to peak) of INF, ADA, ECU, VEDO and RITU. The peak concentration for VEDO and RITU was also added to samples with known monoclonal gammopathies. All samples were analyzed by SPEP (Helena Laboratories) and IFE (Sebia); sera containing peak concentrations of mAbs were reflexed to electrospray-time-of-flight mass spectrometry (AbSciex Triple TOF 5600) for the intact light chain monoclonal immunoglobulin rapid accurate mass measurement (miRAMM).Results: For all mAbs tested, no quantifiable M-spikes were observed by SPEP at any concentration analyzed. Small γ fraction abnormalities were noted on SPEP for VEDO at 300 μg/mL and RITU at 400 μg/mL, with identification of small IgG κ proteins on IFE. Using miRAMM for peak samples, therapeutic mAbs light chain accurate masses were identified above the polyclonal background and were distinct from endogenous monoclonal gammopathies.Conclusions: MAbs should not be easily confounded with plasma cell dyscrasias in patients undergoing therapy except when a SPEP and IFE are performed within a couple of days from infusion (peak). In ambiguous cases the use of the miRAMM technology could precisely identify the therapeutic mAb distinct from any endogenous monoclonal protein.Keywords
This publication has 10 references indexed in Scilit:
- Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC–MS/MSInternational Immunopharmacology, 2015
- Detecting monoclonal immunoglobulins in human serum using mass spectrometryMethods, 2015
- Phenotyping Polyclonal Kappa and Lambda Light Chain Molecular Mass Distributions in Patient Serum Using Mass SpectrometryJournal of Proteome Research, 2014
- Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal GammopathyJournal of Proteome Research, 2014
- Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot studyThe Lancet Neurology, 2013
- Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresisBritish Journal of Haematology, 2011
- Interference of Monoclonal Antibody Therapies with Serum Protein Electrophoresis TestsClinical Chemistry, 2010
- Therapeutic antibodies for autoimmunity and inflammationNature Reviews Immunology, 2010
- Screening Panels for Detection of Monoclonal GammopathiesClinical Chemistry, 2009
- Monoclonal Antibody Pharmacokinetics and PharmacodynamicsClinical Pharmacology & Therapeutics, 2008